Sumana Narasimhan, MD
Pediatric Endocrinology
Highlights
Age Groups Seen
- Child
- Adolescent
Languages
- Hindi
- Tamil
- English
Gender
FemaleAbout Sumana Narasimhan
Biography
Dr Narasimhan completed her training in pediatric endocrinology at Cincinnati Children's Medical Center in 2005 and then worked at Rainbow Babies and Children's Hospital until 2015. Her main interests include general pediatric endocrinology, puberty, growth and hormone problems in survivors of childhood cancer.
Dr Narasimhan is an Associate Professor of Pediatrics at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University
Dr Narasimhan serves on the Senior Medical Staff Committee for Camp Ho Mita Koda and on the planning committee for Type 1 Nation, an annual summit for Diabetes organized by the JDRF in Northeast Ohio.
Dr Narasimhan is a member of the High-Five Cancer Survivor's Clinic. The High-Five Cancer Survivor's Clinic is a group of professionals who work hand in hand to meet the unique needs of our childhood cancer survivor patients and their families.
Locations
- Cleveland Clinic Children's Outpatient Center
- 8950 Euclid Avenue, Cleveland, OH 44106
- Get Directions
Education & Board Certifications
Education
- Fellowship: University of Cincinnati Hospital/Cincinnati Children's Hospital, 2005
- Residency: New York Medical College, 1996
- Residency: Lady Hardinge Medical College, Delhi University, 1993
- Medical Education: Lady Hardinge Medical College, Delhi University, 1990
Board Certifications
- Pediatric Endocrinology: American Board of Pediatrics, 2009
- Pediatrics: American Board of Pediatrics, 1996
Awards
- US News and World Report/ Castle Conolly Top Doctor
- Best Doctors 2009- present
- Dr Kazi Uzair memorial award for Dedication and Commitment in the Care of Children: 1996
Research & Publications
See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.
As of 2026-01-06, Dr. Narasimhan has reported no financial relationship with industry that is applicable to this listing.
In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.